DTI Grant Awarded

Futura Medical PLC
05 December 2003




Press Release                                               05 December 2003





             Futura Medical wins DTI Research and Development Grant



Futura Medical plc ('Futura'), the AIM-listed pharmaceutical and medical device
group that develops innovative products for the sexual healthcare market, is
pleased to announce that its subsidiary Futura Medical Developments Limited, has
been awarded a Research Project Grant under the new Grant for Research and
Development Scheme of the Department of Trade & Industry.



The grant will provide up to £75,000 for the initial stages of research and
development of Futura's FLD500 product.



Futura's grant submission was assessed on its level of innovation, technical
risk, the management team and the overall business proposition.



The award is the Department of Trade and Industry's initiative, which recently
replaced the Smart scheme, providing grants to help individuals and small and
medium-sized businesses to research and develop technologically innovative
products and processes.



For further information:
Futura Medical plc
James Barder, Chief Executive                       Tel: [phone]
mailto:[e-mail]             www.futuramedical.co.uk



Media enquiries:
Bankside
Peter Curtain / Alex Tweed                          Tel: [phone]
mailto:[e-mail]                 www.bankside.com



Notes to Editors:



Futura Medical plc



Futura Medical ('Futura' or 'the Company') is an AIM-listed pharmaceutical and
medical device group developing innovative products for sexual health.  The
Company is developing a portfolio of products with the intention of licensing
their manufacture and distribution to major pharmaceutical and healthcare
groups.   Several agreements have been signed.



Futura's primary focus is on Over the Counter (OTC) products with particular
appeal to men and women who are reluctant to discuss potentially embarrassing
sexual matters with their doctors.



In June 2003 the Company's first product, MED2001, a rub-on cream for erectile
dysfunction (ED), completed its Phase II study, which demonstrated a good safety
profile and efficacy trends.  MED2001 is likely to enter Phase III trials in
early 2004, prior to a regulatory submission for licensing in 2005.



A trial to assess the safety of MED2001 in angina patients is underway.  Normal
medications taken by angina patients prevent the use of most currently available
ED treatments.



CSD500 is a latex condom incorporating within its teat a gel to help healthy men
maintain an erection throughout intercourse, so reducing condom slippage.  The
regulatory dossier is scheduled for submission in 2004 and an exclusive
agreement with SSL International plc, the maker of DurexTM, to distribute the
product is expected to be income generating by 2005.



FLD500, aimed primarily at female partners of male condom users, will help women
maintain lubrication during intercourse, thereby reducing the risk of condom
failure.



www.futuramedical.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange